The incidence rate of nausea in patients who receive tirzepatide was 20.43%, while the incidence rate in the comparators was 10.47%, and it was significantly higher in the tirzepatide arm than in the comparators as shown in Figure 4 (RR, 2.90
It means that the goal of your taper should not just be minimizing weight regain but specifically keeping regain below that 25% threshold where the health benefits start to unravel
Im saving your ass
Additional symptoms of the genetic disorder may become apparent from early childhood: a heightened interest in food and easy weight gain underdeveloped genitals sleep conditions and disorders, including sleep apnea (disrupted breathing while sleeping) and excessive daytime sleepiness language delays and speech problems cognitive issues and learning disabilities behavioral problems, such as stubbornness, temper tantrums, and obsessive-compulsive behaviors like skin picking decreased pain sensitivity thick saliva and tooth issues
Yet a patient who presents after an overdose the clearest possible sign of life-threatening opioid use disorder often leaves without being started on buprenorphine, the very medication that could: reduce craving prevent another overdose decrease repeat ER visits and save their life We have built a system in Kentucky where access to addictive opioids is simpler than access to addiction treatment
The SmPC highlights risks of pancreatitis, gallbladder disease, dehydration potentially leading to acute kidney injury (particularly with prolonged vomiting/diarrhoea), and hypoglycaemia when used with insulin or sulfonylureas
